Liraglutide (Victoza)

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Atherosclerotic Cardiovascular Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Victoza: type 2 diabetes
Product first approved 2010novonordisk.com
EU
  • Victoza: type 2 diabetes mellitus (adults, adolescents and children from 10 years)
Product first approved 2009EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (69)
Atherosclerotic Cardiovascular Disease
NCT05467514 · David Sanchez Garcia
2022-07-01 – 2023-02-28 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT06559722 · Tonghua Dongbao Pharmaceutical Co.,Ltd
2024-08 – 2026-02 · Type 2 Diabetes
What this study did
NCT05767255 · Hospital Universitario San Ignacio
2022-12-01 – 2023-08-30 · Diabetes Mellitus, Type 2 Treated With Insulin
What this study did
NCT04057261 · RWTH Aachen University
2020-11 – 2022-11 · Type 2 Diabetes, Cardiovascular Diseases
What this study did
NCT05360147 · Third Military Medical University
2021-01-20 – 2021-05-10 · Type 2 Diabetes Mellitus
What this study did
NCT01794143 · GRADE Study Group
2013-05 – 2021-04-30 · Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
What this study did
NCT02889510 · Lecube, Albert, M.D.
2016-10-04 – 2019-12-16 · Type 2 Diabetes
What this study did
NCT03421119 · Cinnagen
2019-06-20 – 2019-12-01 · Diabetes Mellitus, Type 2
What this study did
NCT01779362 · RISE Study Group
2013-04 – 2019-08 · Prediabetes, Type 2 Diabetes
What this study did
NCT03172494 · Novo Nordisk A/S
2017-05-26 – 2019-07-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01234649 · Woman's
2011-08-11 – 2019-06-14 · Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
What this study did
NCT03707171 · Third Military Medical University
2018-10-01 – 2019-05-01 · Type 2 Diabetes Mellitus
What this study did
NCT02501161 · Novo Nordisk A/S
2016-01-31 – 2018-10-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02964247 · Novo Nordisk A/S
2017-03-03 – 2018-05-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02607306 · Novo Nordisk A/S
2015-11-18 – 2017-12-22 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02505334 · Novo Nordisk A/S
2015-07-21 – 2017-11-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02638805 · Intarcia Therapeutics
2015-12 – 2017-10 · Diabetes Mellitus, Type 2
What this study did
NCT02043054 · University of Leicester
2013-12-16 – 2017-09-29 · Type 2 Diabetes Mellitus, Cardiovascular Disease
What this study did
NCT02718950 · University of Campinas, Brazil
2016-06 – 2017-04 · Obesity, Type 2 Diabetes Mellitus
What this study did
NCT02420262 · Novo Nordisk A/S
2015-07-26 – 2016-10-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02298192 · Novo Nordisk A/S
2014-11-21 – 2015-12-23 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01628445 · University of Manitoba
2012-08 – 2015-11 · Type 2 Diabetes
What this study did
NCT01937598 · Michael A. Nauck
2013-08 – 2015-06 · Type 2 Diabetes
What this study did
NCT01952145 · Novo Nordisk A/S
2013-09-20 – 2014-11-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01270789 · Mount Sinai Hospital, Canada
2011-01 – 2014-05 · Type 2 Diabetes
What this study did
NCT01676116 · Novo Nordisk A/S
2012-08-29 – 2014-03-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01664247 · Novo Nordisk A/S
2012-10-01 – 2013-12-31 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01617434 · Novo Nordisk A/S
2012-09 – 2013-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01620489 · Novo Nordisk A/S
2012-06-14 – 2013-08-20 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01512108 · Novo Nordisk A/S
2012-01-10 – 2013-04-26 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01572740 · Novo Nordisk A/S
2012-04-05 – 2013-03-27 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01392573 · Novo Nordisk A/S
2011-11-28 – 2012-10-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01388361 · Novo Nordisk A/S
2011-09 – 2012-07 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00856986 · Novo Nordisk A/S
2009-03 – 2010-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00700817 · Novo Nordisk A/S
2008-06 – 2010-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00620282 · Novo Nordisk A/S
2008-02 – 2010-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00518882 · Novo Nordisk A/S
2007-08 – 2009-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00614120 · Novo Nordisk A/S
2008-01 – 2009-02 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00294723 · Novo Nordisk A/S
2006-02 – 2008-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00393718 · Novo Nordisk A/S
2006-11 – 2008-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00395746 · Novo Nordisk A/S
2006-10 – 2008-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 2/3 (5)
Other / comorbidity
NCT01879917 · Hvidovre University Hospital
2014-02 – 2018-08 · Diabetes Mellitus, Type 1
What this study did
NCT02351232 · Hvidovre University Hospital
2015-02 – 2016-10 · Type 1 Diabetes
What this study did
NCT02584582 · Hvidovre University Hospital
2015-07 – 2015-11 · Type 1 Diabetes
What this study did
NCT01610934 · University Hospital, Gentofte, Copenhagen
2012-08 – 2013-08 · Maturity-onset Diabetes of the Young
What this study did
NCT00993720 · Hvidovre University Hospital
2009-10 – 2010-10 · Diabetes Mellitus
What this study did
Phase 2 (37)
Atherosclerotic Cardiovascular Disease
NCT02315001 · King's College London
2014-01 – 2015-03 · Ischaemic Heart Disease, Coronary Heart Disease, Chronic Stable Angina
What this study did
Type 2 Diabetes
NCT06976619 · Mayo Clinic
2025-10-03 – 2029-03-31 · Type 1 Diabetes, Type 2 Diabetes
What this study did
NCT04535960 · University Health Network, Toronto
2019-03-14 – 2021-03-16 · Type 2 Diabetes Mellitus
What this study did
NCT03426085 · Eastern Virginia Medical School
2016-05 – 2020-08 · Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication
What this study did
NCT02472717 · University Health Network, Toronto
2015-05 – 2016-10 · Psoriatic Arthritis, Psoriasis, Impaired Glucose Tolerance, Type 2 Diabetes
What this study did
NCT01425580 · Thomas Nystrom
2012-01 – 2016-08 · Congestive Heart Failure, Type 2 Diabetes Mellitus
What this study did
NCT02113332 · Vastra Gotaland Region
2013-01 – 2014-08 · Type 2 Diabetes Mellitus
What this study did
NCT01399645 · Centre hospitalier de l'Université de Montréal (CHUM)
2011-05 – 2014-06 · Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes
What this study did
NCT01725126 · GlaxoSmithKline
2013-02-10 – 2013-09-12 · Obesity
What this study did
NCT01516476 · Hoffmann-La Roche
2011-11 – 2012-01 · Diabetes Mellitus Type 2
What this study did
NCT00696657 · Novo Nordisk A/S
2008-06-03 – 2009-02-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00154414 · Novo Nordisk A/S
2005-01 – 2006-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00154401 · Novo Nordisk A/S
2005-01 – 2005-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01508949 · Novo Nordisk A/S
2001-06 – 2002-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01508923 · Novo Nordisk A/S
2001-05 – 2002-02 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01511198 · Novo Nordisk A/S
2001-02 – 2001-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01509755 · Novo Nordisk A/S
2000-10 – 2001-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07029009 · Mansa
2025-05-08 – 2027-01 · Maturity Onset Diabetes of the Young
What this study did
NCT02611232 · University of Oulu
2015-12 – 2024-06 · Type 1 Diabetes
What this study did
NCT04763564 · University of North Carolina, Chapel Hill
2022-03-22 – 2023-10-16 · Pouchitis, Irritable Pouch Syndrome
What this study did
NCT02953665 · Cedars-Sinai Medical Center
2017-04-03 – 2022-08-03 · Parkinson Disease
What this study did
NCT03712098 · Rebecca Ashare
2018-11-29 – 2022-05-25 · Smoking Cessation, Weight, Body
What this study did
NCT02898506 · University of Oulu
2016-03 – 2021-06 · Type 1 Diabetes
What this study did
NCT02908087 · University of Oulu
2016-03 – 2021-05 · Type 1 Diabetes
What this study did
NCT03371862 · Imperial College London
2017-10-20 – 2020-09-30 · Short Bowel Syndrome
What this study did
NCT02617654 · Per-Ola Carlsson
2015-11 – 2020-09 · Type 1 Diabetes
What this study did
NCT01843075 · Imperial College London
2014-01 – 2019-12 · Alzheimer's Disease
What this study did
NCT01845259 · Psychiatric Centre Rigshospitalet
2013-04 – 2017-03 · Impaired Glucose Tolerance Associated With Drugs
What this study did
NCT02408705 · Medical University of Graz
2015-01 – 2016-05 · Type 1 Diabetes Mellitus
What this study did
NCT01800968 · Duke University
2013-04 – 2015-10 · Acute Heart Failure
What this study did
NCT02284230 · Bo Feldt-Rasmussen
2014-12 – 2015-08 · Kidney Failure, Chronic, Prediabetic State
What this study did
NCT01782261 · Medical University of Graz
2012-02 – 2015-02 · Type 1 Diabetes
What this study did
NCT01755416 · Albert Einstein College of Medicine
2013-01 – 2015-01 · Type 1 Diabetes
What this study did
NCT01237119 · University of Birmingham
2010-08 – 2014-07 · Nonalcoholic Steatohepatitis
What this study did
NCT01206101 · Novo Nordisk A/S
2012-03-21 – 2013-06-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 1/2 (6)
Type 2 Diabetes
NCT05268237 · Biolingus
2023-04-25 – 2026-03 · Diabete Type 2
What this study did
NCT02960659 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2017-05-09 – 2022-05-20 · Type 2 Diabetes
What this study did
NCT01954147 · Diabetes Care Center of Nanjing Military Command
2013-10 – 2015-10 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT03011021 · Second Xiangya Hospital of Central South University
2017-01 – 2025-06 · Type1 Diabetes Mellitus, Autoimmune Diabetes
What this study did
NCT03182426 · University of Alberta
2017-08-15 – 2024-07-15 · Diabetes Mellitus, Type 1
What this study did
NCT04199728 · Milton S. Hershey Medical Center
2021-10-18 – 2023-09-13 · Opiate Substitution Treatment, Opioid-Related Disorders
What this study did
Phase 1 (50)
Type 2 Diabetes
NCT06439056 · Nanexa AB
2024-05-27 – 2025-07-18 · Type 2 Diabetes
What this study did
NCT05294536 · Sunshine Lake Pharma Co., Ltd.
2020-06-22 – 2020-11-27 · Type 2 Diabetes
What this study did
NCT02650206 · Stanford University
2015-01 – 2019-09-27 · Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
What this study did
NCT05029076 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2019-05-21 – 2019-07-01 · Type 2 Diabetes
What this study did
NCT03292185 · Novo Nordisk A/S
2017-09-29 – 2018-01-02 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02059564 · Hanmi Pharmaceutical Company Limited
2013-12 – 2014-12 · Diabetes Mellitus
What this study did
NCT01870297 · Eli Lilly and Company
2013-06 – 2014-12 · Type 2 Diabetes Mellitus
What this study did
NCT01916174 · Novo Nordisk A/S
2013-08 – 2013-11 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01473953 · Novo Nordisk A/S
2011-10 – 2012-03 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT00943501 · Novo Nordisk A/S
2009-11 – 2011-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01373450 · Merck Sharp & Dohme LLC
2011-06 – 2011-07 · Type 2 Diabetes Mellitus
What this study did
NCT00993304 · Novo Nordisk A/S
2009-10 – 2010-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00873223 · Novo Nordisk A/S
2009-03 – 2009-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01511692 · Novo Nordisk A/S
2005-11 – 2007-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01517555 · Novo Nordisk A/S
2006-10 – 2007-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01508858 · Novo Nordisk A/S
2006-11 – 2007-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01516255 · Novo Nordisk A/S
2006-07 – 2006-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01507389 · Novo Nordisk A/S
2006-03 – 2006-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01515592 · Novo Nordisk A/S
2006-01 – 2006-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01508806 · Novo Nordisk A/S
2005-08 – 2006-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01615978 · Novo Nordisk A/S
2003-12 – 2004-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01620463 · Novo Nordisk A/S
2002-12 – 2003-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01509742 · Novo Nordisk A/S
2001-04 – 2001-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01511185 · Novo Nordisk A/S
2001-02 – 2001-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01507311 · Novo Nordisk A/S
1999-09 – 1999-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01507285 · Novo Nordisk A/S
1999-08 – 1999-11 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
Other / comorbidity
NCT06449703 · Tonghua Dongbao Pharmaceutical Co.,Ltd
2024-05-06 – 2024-06-16 · Healthy
What this study did
NCT05444569 · Eli Lilly and Company
2022-08-08 – 2023-02-24 · Healthy
What this study did
NCT03632759 · Carla Greenbaum, MD
2018-08-15 – 2021-11-09 · Type 1 Diabetes Mellitus
What this study did
NCT02231658 · Profil Institut für Stoffwechselforschung GmbH
2015-07-16 – 2018-07-23 · Diabetes Mellitus
What this study did
NCT02140983 · Stanford University
2013-08 – 2017-02 · Insulin Resistance, Dementia
What this study did
NCT01856790 · Jennifer Sherr
2013-02 – 2015-11 · Type 1 Diabetes
What this study did
NCT02109315 · Anna Cruceta
2014-05 – 2015-05 · Type 1 Diabetes Mellitus
What this study did
NCT01550653 · University of Luebeck
2012-05 – 2013-12 · Healthy
What this study did
NCT01536665 · Novo Nordisk A/S
2012-02 – 2012-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01319240 · Novo Nordisk A/S
2011-03 – 2011-05 · Diabetes, Healthy
What this study did
NCT00983021 · Novo Nordisk A/S
2009-09 – 2009-12 · Diabetes, Healthy
What this study did
NCT01513525 · Novo Nordisk A/S
2007-02 – 2007-05 · Diabetes, Healthy
What this study did
NCT01515553 · Novo Nordisk A/S
2007-01 – 2007-04 · Diabetes, Healthy
What this study did
NCT01518166 · Novo Nordisk A/S
2006-05 – 2007-04 · Diabetes, Healthy
What this study did
NCT01517568 · Novo Nordisk A/S
2006-11 – 2006-12 · Diabetes, Healthy
What this study did
NCT01515579 · Novo Nordisk A/S
2006-04 – 2006-06 · Diabetes, Healthy
What this study did
NCT01514487 · Novo Nordisk A/S
2005-01-13 – 2005-03-30 · Diabetes, Healthy
What this study did
NCT01508897 · Novo Nordisk A/S
2004-05-28 – 2004-06-30 · Diabetes, Healthy
What this study did
NCT01507337 · Novo Nordisk A/S
2004-04 – 2004-06 · Diabetes, Healthy
What this study did
NCT01620476 · Novo Nordisk A/S
2003-09 – 2004-03 · Diabetes, Healthy
What this study did
NCT01511159 · Novo Nordisk A/S
2001-10 – 2001-12 · Diabetes, Healthy
What this study did
NCT01507272 · Novo Nordisk A/S
1999-03 – 1999-12 · Diabetes, Healthy
What this study did
Phase 4 (78)
Atherosclerotic Cardiovascular Disease
NCT03260881 · University of Miami
2018-09-01 – 2024-09-05 · Type2 Diabetes, Coronary Artery Disease
What this study did
NCT04881110 · University of Campania Luigi Vanvitelli
2021-02-01 – 2022-12-31 · Type 2 Diabetes, Peripheral Arterial Disease
What this study did
NCT01595789 · Haugaard, Steen Bendix, M.D., DMSc
2012-05 – 2015-07 · Coronary Artery Disease, Diabetes Mellitus, Type 2
What this study did
Type 2 Diabetes
NCT07244003 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2025-03-29 – 2028-06-30 · T2DM (Type 2 Diabetes Mellitus)
What this study did
NCT03883412 · University of Virginia
2019-02-28 – 2027-12 · Type2 Diabetes
What this study did
NCT06408532 · Peking University People's Hospital
2024-04-30 – 2025-02-28 · Diabetes Mellitus, Type 2
What this study did
NCT03087032 · The First Affiliated Hospital of Xiamen University
2019-01-10 – 2025-02-10 · Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)
What this study did
NCT02344186 · Temple University
2014-05 – 2023-12-31 · Type 2 Diabetes
What this study did
NCT04657939 · University of Leeds
2020-12-01 – 2022-10-31 · Diabetes Mellitus, Type 2
What this study did
NCT05360537 · University of Palermo
2021-04-01 – 2022-04-20 · Diabetes Mellitus, Type 2
What this study did
NCT04146155 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-05-01 – 2021-12-31 · Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus
What this study did
NCT02686177 · Assistance Publique - Hôpitaux de Paris
2016-05-18 – 2021-05-28 · Type 2 Diabetes
What this study did
NCT02198209 · Cedars-Sinai Medical Center
2019-12 – 2020-12 · Type 2 Diabetes
What this study did
NCT01795248 · Tina Vilsboll
2012-07 – 2020-09 · Gestational Diabetes Mellitus
What this study did
NCT01919489 · Emory University
2014-03 – 2020-08-30 · Type 2 Diabetes
What this study did
NCT02535299 · Third Military Medical University
2016-06 – 2019-12 · GLP-1;Metformin;Telomere-telomerase System;Par-4
What this study did
NCT02655770 · Copenhagen University Hospital, Rigshospitalet
2016-02 – 2019-12 · Diabetes Mellitus Type 2, Diastolic Dysfunction, Cardiac MRI, Myocardial Perfusion
What this study did
NCT02721888 · Centre Hospitalier Universitaire Dijon
2012-07-10 – 2019-10-02 · Type 2 Diabetes
What this study did
NCT03449654 · Steno Diabetes Center Copenhagen
2017-10-26 – 2019-08-16 · Diabetes Mellitus, Type 2
What this study did
NCT02765399 · Helsinki University Central Hospital
2015-02-01 – 2019-02-28 · Type 2 Diabetes
What this study did
NCT02743598 · Temple University
2016-09 – 2018-09 · HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
What this study did
NCT02660047 · Leiden University Medical Center
2015-08 – 2018-03-09 · Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease, Diastolic Dysfunction, Fatty Liver
What this study did
NCT01966978 · University of Texas Southwestern Medical Center
2014-11 – 2017-12 · Diabetes Mellitus, Type 2, Diabetes
What this study did
NCT02147925 · Sun Yat-sen University
2014-08 – 2017-04 · Non-alcoholic Fatty Liver Disease
What this study did
NCT02055014 · Sandwell & West Birmingham Hospitals NHS Trust
2013-07 – 2017-03 · Type 2 Diabetes, Obesity, Diabesity
What this study did
NCT02014740 · University of Miami
2014-03 – 2017-03 · Type 2 Diabetes, Overweight, Obesity
What this study did
NCT02832999 · Yaounde Central Hospital
2016-01 – 2016-12 · Type 2 Diabetes Mellitus
What this study did
NCT02299388 · Tulane University School of Medicine
2014-10 – 2016-12 · Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
What this study did
NCT02503943 · Third Affiliated Hospital of Third Military Medical University
2015-05 – 2016-09 · Type 2 Diabetes, Overweight, Obesity, Masked Hypertension
What this study did
NCT02674893 · Centre Hospitalier Universitaire Dijon
2014-02-04 – 2016-08-31 · Type 2 Diabetes, Overweight
What this study did
NCT01505673 · Ildiko Lingvay
2012-01 – 2016-06 · Type 2 Diabetes Mellitus, Obesity
What this study did
NCT01761318 · Leiden University Medical Center
2013-11 – 2016-03 · Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease, Diastolic Dysfunction, Fatty Liver
What this study did
NCT01790308 · Sun Yat-sen University
2013-02 – 2015-12 · Diabetes Mellitus, Type 2
What this study did
NCT02072096 · Eli Lilly and Company
2014-02 – 2015-10 · Diabetes Mellitus, Type 2
What this study did
NCT02501850 · Hospital Universitari Vall d'Hebron Research Institute
2014-10 – 2015-10 · Diabetes Mellitus Type 2
What this study did
NCT03068065 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2014-05 – 2015-10 · Non-Alcoholic Fatty Liver Disease, Type2 Diabetes
What this study did
NCT01744236 · Amsterdam UMC, location VUmc
2013-04 – 2015-08 · Type 2 Diabetes
What this study did
NCT01907854 · Novo Nordisk A/S
2013-12-02 – 2015-06-15 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01973231 · Novo Nordisk A/S
2013-10 – 2014-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02008682 · Novo Nordisk A/S
2013-12 – 2014-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01917656 · Novo Nordisk A/S
2014-01-09 – 2014-09-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01785043 · Anna Cruceta
2013-03 – 2014-09 · DIABETES Mellitus Type 2 Not Well Controlled
What this study did
NCT01499108 · Peter Rossing
2012-08 – 2014-08 · Type 2 Diabetes
What this study did
NCT01597531 · East Carolina University
2012-06 – 2014-06 · Type 2 Diabetes, Gastric Banding
What this study did
NCT01455441 · Tina Vilsboll
2011-10 – 2014-06 · Type 2 Diabetes
What this study did
NCT01931982 · Bispebjerg Hospital
2013-05 – 2014-04 · Type 2 Diabetes, Microvascular Dysfunction
What this study did
NCT01755572 · Mount Sinai Hospital, Canada
2013-01 – 2014-03 · Type 2 Diabetes, Systolic Hypertension
What this study did
NCT01664676 · University of Aarhus
2012-12 – 2014-02 · Type 2 Diabetes Mellitus
What this study did
Early phase / not applicable (31)
Atherosclerotic Cardiovascular Disease
Type 2 Diabetes
NCT02879409 · Weill Cornell Medical College in Qatar
2016-11 – 2026-10-01 · Diabetes Mellitus Type 2
What this study did
NCT05313529 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2022-10-08 – 2026-07-01 · Type 2 Diabetes Mellitus, Mild Cognitive Impairment
What this study did
NCT04324229 · Turku University Hospital
2020-02-07 – 2025-04-09 · Gestational Diabetes
What this study did
NCT03948347 · First Affiliated Hospital of Jinan University
2019-06-25 – 2024-06 · Ischemic Stroke, Transient Ischemic Attack, Type 2 Diabetes Mellitus
What this study did
NCT04829903 · Corporacion Parc Tauli
2020-01-02 – 2021-11-20 · Type 2 Diabetes Treated With Insulin, Obesity, Adolescent Obesity
What this study did
NCT04190160 · Stefano Rizza
2018-11-19 – 2021-03-25 · Type2 Diabetes
What this study did
NCT02324842 · The University of Texas Health Science Center at San Antonio
2014-11 – 2019-03-31 · Type 2 Diabetes Mellitus
What this study did
NCT01232946 · Indiana University
2012-01 – 2017-09-08 · Type 2 Diabetes
What this study did
NCT02783196 · Tel Aviv University
2016-07 – 2017-06 · Type 2 Diabetes
What this study did
NCT02036372 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2014-01 – 2017-01 · Diabetes Mellitus Type II
What this study did
NCT01740921 · Royal Devon and Exeter NHS Foundation Trust
2011-01 – 2016-02 · Type 2 Diabetes
What this study did
NCT01472640 · Flyvbjerg, Allan, DMSc
2011-11 – 2015-10 · Hyperglycemia, Chronic Heart Failure
What this study did
NCT01363609 · Amsterdam UMC, location VUmc
2011-10 – 2015-01 · Obesity, Type 2 Diabetes
What this study did
NCT01392898 · Radboud University Medical Center
2012-02 – 2014-05 · Type 2 Diabetes Mellitus
What this study did
NCT01599338 · Centre Hospitalier Universitaire Dijon
2011-01 – 2011-09 · Type 2 Diabetes Mellitus, Overweight
What this study did
Other / comorbidity
NCT06818292 · Nils Opel
2024-10-21 – 2024-12-06 · Healthy
What this study did
NCT06500130 · Alimetry
2024-05-30 – 2024-11-30 · Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
What this study did
NCT05390307 · Dasman Diabetes Institute
2023-04-01 – 2024-01-01 · Type 1 Diabetes
What this study did
NCT04137328 · Fudan University
2019-11-30 – 2022-11-30 · Diabetic Neuropathic Pain
What this study did
NCT02930265 · Chinese PLA General Hospital
2016-09 – 2018-03 · Ischemic Cardiomyopathy
What this study did
NCT02138045 · Aalborg University Hospital
2014-05 – 2017-02 · Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
What this study did
NCT02777073 · University at Buffalo
2016-03-01 – 2016-12-31 · Type 1 Diabetes
What this study did
NCT02507128 · Chen Wei Ren, MD
2015-07 – 2016-07 · Acute ST-segment Elevation Myocardial Infarction
What this study did
NCT02490176 · Chinese PLA General Hospital
2015-07 – 2016-07 · Heart Failure
What this study did
NCT02001363 · Chen Wei Ren, MD
2013-11 – 2016-03 · Acute Myocardial Infarction
What this study did
NCT01575301 · University of Dundee
2011-03 – 2015-12-11 · Diabetes
What this study did
NCT02104037 · Mikkel Christensen
2012-01 – 2013-12 · Liraglutide Blood-brain Transfer
What this study did
NCT01460069 · Annesofie Faurschou
2011-10 – 2013-05 · Psoriasis
What this study did
NCT01469351 · University of Aarhus
2012-01 – 2013-04 · Alzheimers Disease
What this study did
NCT01451905 · University Hospital, Gentofte, Copenhagen
2011-08 – 2012-12 · Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI
What this study did
Used as active comparator (26)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (11)
Type 2 Diabetes
NCT04373967 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-04-29 – 2021-12-02 · Type 2 Diabetes
What this study did
NCT03018028 · Novo Nordisk A/S
2017-01-10 – 2018-08-15 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03191396 · Novo Nordisk A/S
2017-06-27 – 2018-08-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02863419 · Novo Nordisk A/S
2016-08-10 – 2018-03-30 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01733758 · GlaxoSmithKline
2013-02 – 2015-02 · Diabetes Mellitus, Type 2
What this study did
NCT01558271 · Eli Lilly and Company
2012-03 – 2014-05 · Type 2 Diabetes Mellitus
What this study did
NCT01624259 · Eli Lilly and Company
2012-06 – 2013-11 · Type 2 Diabetes
What this study did
NCT01296412 · Merck Sharp & Dohme LLC
2011-03-11 – 2012-02-29 · Diabetes Mellitus, Type 2
What this study did
NCT01128894 · GlaxoSmithKline
2010-05 – 2011-09 · Diabetes Mellitus, Type 2
What this study did
NCT01029886 · AstraZeneca
2010-01 – 2011-04 · Type 2 Diabetes Mellitus
What this study did
Phase 2 (10)
Type 2 Diabetes
NCT03555994 · MedImmune LLC
2018-05-31 – 2021-04-14 · Type 2 Diabetes Mellitus
What this study did
NCT03235050 · AstraZeneca
2017-08-02 – 2019-06-14 · Diabetes Mellitus, Type 2
What this study did
NCT02973321 · Sanofi
2016-12-02 – 2017-12-27 · Type 2 Diabetes Mellitus
What this study did
NCT02492763 · Merck Sharp & Dohme LLC
2015-07-27 – 2017-04-18 · Type II Diabetes Mellitus
What this study did
NCT02461589 · Novo Nordisk A/S
2015-09-21 – 2016-10-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02205528 · Novo Nordisk A/S
2014-08-18 – 2015-09-15 · Diabetes, Diabetes Mellitus Type 2
What this study did
NCT02057172 · Hanmi Pharmaceutical Company Limited
2014-01 – 2014-12 · Type 2 Diabetes
What this study did
NCT01175473 · Sanofi
2010-08 – 2010-11 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
Phase 1 (4)
Type 2 Diabetes
NCT03115099 · Eli Lilly and Company
2017-05-31 – 2018-04-05 · Diabetes Mellitus, Type 2
What this study did
NCT01982630 · Merck Sharp & Dohme LLC
2013-11-07 – 2014-10-03 · Diabetes Mellitus
What this study did
Other / comorbidity
NCT05794581 · Carmot Therapeutics, Inc.
2023-03-21 – 2024-04-06 · Type 1 Diabetes
What this study did
NCT05225974 · The Affiliated Hospital of Qingdao University
2021-07-16 – 2021-08-19 · Therapeutic Equivalency
What this study did
Phase 4 (1)
Type 2 Diabetes
NCT01117350 · Sanofi
2010-07 – 2013-03 · Diabetes Mellitus, Type 2
What this study did

Competitive landscape

This mechanism is crowded: 50 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Liraglutide (Victoza): this drugApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Saxenda)
Approved(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy Tablets)
Approved(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HDG1901Phase 3PeptideGLP-1 receptorPartial signal
NCT06739044: HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met.
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
HenagliflozinPhase 3Small moleculeSodium-glucose cotransporter 2 (SGLT2)Reliable signal
NCT04390295: Placebo-adjusted LS mean HbA1c change at Week 24: -0.76% (5 mg) and -0.80% (10 mg) vs placebo, both P < .0001.
NCT03159052: Placebo-adjusted LS mean HbA1c change at Week 24: -0.91% (5 mg) and -0.94% (10 mg) vs placebo, both P < .001.
HR17031Phase 3PeptideInsulin receptor / GLP-1 receptor (combination)Partial signal
NCT06881264: Week 26 HbA1c change, LS mean: HR17031 -1.85% vs insulin glargine -1.06% (sponsor-reported)
NCT06871761: HbA1c change from baseline at week 26: HR17031 -1.53% vs insulin glargine -0.25%; LS-mean difference -1.29% (95% CI -1.48 to -1.10), P<0.0001 (sponsor-reported, ADA 2026)
IcoSema (Kyinsu)Phase 3PeptideInsulin receptor (basal), GLP-1 receptorPartial signal
NCT06269107: (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001)
NCT05352815: Change in Glycated Haemoglobin (HbA1c) (Baseline (Week 0), Week 52): IcoSema -1.6 Percentage point of HbA1c (Standard Deviation 0.99) vs Insulin Icodec -0.9 Percentage point of HbA1c (Standard Deviation 1.01)
Insulin Sudelidec (INS068)Phase 3PeptideInsulin receptor (basal)Partial signal
NCT05699408: Change in HbA1c at Week 26 (Study 302, oral-antidiabetic-drug background, n=513): insulin sudelidec (INS068) -1.34% vs insulin glargine -1.37%; between-group difference 0.02% (95% CI -0.14% to 0.18%)
NCT05702073: Change in HbA1c at Week 26 (Study 301, basal-insulin background, n=423): insulin sudelidec (INS068) -0.70% vs insulin glargine -0.83%; between-group difference 0.13% (95% CI -0.05% to 0.31%)
Janagliflozin (Huiyoujing)Phase 3Small moleculeSGLT2Reliable signal
NCT03811548: Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023)
JW0201Phase 3Small moleculeDipeptidyl peptidase-4 (DPP-4)Partial signal
NCT05814393: HbA1c change from baseline at Week 24: -0.83% with JW0201 (anagliptin) add-on vs -0.03% with placebo; between-group difference -0.80 percentage points (95% CI -0.95 to -0.64; P<0.0001)
Lobeglitazone (Duvie)Phase 3Small moleculePPAR-gammaWeak signal
NCT03739125: HbA1c change at 24 weeks vs placebo (Study 1, empagliflozin 10 mg plus metformin background): -0.71% (95% CI -0.88 to -0.55), p<0.001. The publication reports Study 2 (empagliflozin 25 mg background, NCT03627182) separately.
NCT01106131: HbA1c change at week 24: -0.74% lobeglitazone vs -0.74% pioglitazone (difference 0.01%, 95% CI -0.16 to 0.18); noninferior.
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistReliable signalNo reviewed efficacy summary in this indication
MazdutidePhase 3PeptideGLP-1/glucagon receptor (dual)Reliable signal
NCT05606913: HbA1c change from baseline at Week 28: -1.61 percentage points (mazdutide 4mg) and -1.66 percentage points (mazdutide 6mg) vs -1.36 percentage points (dulaglutide 1.5mg); superiority P<.01 for both doses.
NCT05628311: HbA1c change from baseline at week 24: -1.57% (mazdutide 4mg), -2.15% (mazdutide 6mg) vs -0.14% (placebo); mazdutide superior to placebo
MDR-001
Phase 3(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Mitiglinide (Glufast)Phase 3Small moleculeSUR1 (short-acting)Partial signal
NCT01037842: Change in HbA1c from randomization to Week 16 endpoint: metformin+mitiglinide -0.7% (SD 0.6) vs metformin+placebo -0.4% (SD 0.7); difference significant at P=0.002.
NCT00461617: Change in HbA1c from baseline: mitiglinide -0.53% (wk12) / -0.77% (wk20) vs nateglinide -0.58% (wk12) / -0.71% (wk20); intergroup difference 0.05% (95% CI -0.19 to 0.30) at week 12 and 0.06% (95% CI -0.31 to 0.19) at week 20.
NoiiglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPnot yet gradedNo reviewed efficacy summary in this indication
OlatorepatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001)
NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met.
Pegloxenatide (Fulaimei)Phase 3PeptideGLP-1 receptorReliable signal
NCT02477969: Phase 3b add-on-to-metformin trial: proportion achieving HbA1c <7.0% at week 24 was 37.4% (100μg) and 40.6% (200μg) vs 16.8% (placebo).
NCT02477865: Phase 3a monotherapy trial: HbA1c LS-mean change at week 24 was -1.02% (100μg) and -1.34% (200μg) vs -0.17% (placebo), p<0.0001.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT06354660: Change in HbA1c from baseline (7.9%) at Week 40: 4 mg -1.7%, 9 mg -2.0%, 12 mg -1.9%, placebo -0.8%; retatrutide met the primary endpoint.
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)Partial signal
NCT06650007: Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo
NCT06649344: Primary, HbA1c change from baseline to week 36 (non-inferiority vs semaglutide 1 mg, efficacy estimand): ribupatide 4 mg -2.78%, 2 mg -2.34%, semaglutide -2.29%; non-inferiority achieved for both doses (margin and CI not published), and 4 mg statistically superior to semaglutide, met.
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT06589765: Primary, HbA1c change from baseline at week 32 vs dapagliflozin 10 mg (non-inferiority margin 0.4%, primary non-inferiority estimand): 30 mg -0.30% (95% CI -0.51 to -0.09), 60 mg -0.22% (95% CI -0.44 to -0.01), 90 mg -0.40% (95% CI -0.62 to -0.19); non-inferiority met for all three doses (all P<0.0001). Superiority (treatment policy estimand): 90 mg -0.25% (95% CI -0.45 to -0.05; one-sided P=0.0067), 60 mg not significant (P=0.0789).
NCT06672172: OUTSTAND-1 phase 3 T2D trial (placebo-controlled, diet-and-exercise inadequately controlled); enrollment (284) matches this listing exactly. Primary endpoint (HbA1c reduction at Week 32 vs placebo, across 30/60/90mg doses) was met: 1.40-1.68% reduction vs 0.06% for placebo.
Visepegenatide (PB-119)Phase 3PeptideGLP-1 receptorReliable signal
NCT04504396: Change in HbA1c from baseline: -1.25% (95% CI -1.35 to -1.16) with visepegenatide (PB-119) vs -0.68% (95% CI -0.78 to -0.59) with placebo; treatment difference -0.57% (95% CI -0.71 to -0.43), p<0.001.
NCT04504370: LSM change in HbA1c from baseline to week 24: visepegenatide (PB-119) -1.36% (95% CI -1.52 to -1.20) vs placebo -0.63% (95% CI -0.79 to -0.46); treatment difference -0.73% (95% CI -0.96 to -0.50, p<0.001)
Zovaglutide
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
DA-302168SPhase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Ecnoglutide (VRB-101)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Exenatide (PT320)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Regor GLP-1Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
SAL0150Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
TE-8105
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
TifeglipronPhase 2Small moleculeGLP-1 receptorWeak signalNo reviewed efficacy summary in this indication
TTP273Phase 2Small moleculeGLP-1 receptorReliable signal
NCT02653599: Change in HbA1c from baseline at Week 12: placebo-subtracted difference -0.86 percentage points (TTP273 150 mg once daily) and -0.71 percentage points (TTP273 150 mg twice daily); placebo arm HbA1c increased 0.15 percentage points from baseline; described as a statistically significant reduction.
UtreglutidePhase 2PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
VCT220Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
ZT006
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
BMF-650
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
DehydraTECH-CBD / Semaglutide
Phase 1(overall)
CombinationOral peptide delivery platform, GLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
IBI3032
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Liraglutide (HUC2-676)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08642534
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08656795
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Semaglutide (DWRX5003)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
XW014Phase 1Small moleculeGLP-1 receptorWeak signalNo reviewed efficacy summary in this indication
MGL-2086
—(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 111 furthest-along competitors are listed; 55 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Liraglutide (Victoza) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 4Atrial FibrillationActive not recruiting
Est. primary completion 2026-12-31 · NCT03856632 · CT.gov ↗
What to watch
2027 (4)
March 2027 (1)
Phase 3Delirium, PostoperativeRecruiting
Est. primary completion 2027-03-31 · NCT06361238 · CT.gov ↗
What to watch
April 2027 (1)
Phase 4Metabolic SyndromeRecruiting
Est. primary completion 2027-04-30 · NCT04575844 · CT.gov ↗
What to watch
June 2027 (1)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-06 · NCT03883412 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-12-31 · NCT07244003 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Phase 4Healthy, Growth Hormone DeficiencyRecruiting
Est. primary completion 2028-04-30 · NCT05681299 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Type 2 DiabetesRecruiting
Est. primary completion 2028-10-30 · NCT06976619 · CT.gov ↗
What to watch

See the full readout calendar ↗